Boltz raises $110M Series A for AI biomolecular design, already working with 6 top pharma cos
GabriCorso · x · 2026-11-19
Boltz, an AI-powered biomolecular design company, has raised a $110M Series A led by Bessemer Venture Partners. Molecular token usage by its users has grown 50-fold since June, and it counts partnerships with 6 of the world's 20 largest pharma companies. Founder Gabri Corso and team aim to bring AI-driven biomolecular design to every scientist.
More from Venture
- Gary Marcus amplifies warning of an AI bubble chain reaction into a financial crisis — GaryMarcus · 2026-11-19
- Listicle scaling doesn't last: SEOs watch mass-produced listicles lose rankings — gaganghotra_ · 2026-11-19
- Agentcard raises $8M to let agents buy from 5,000+ stores via Stripe Link — jeff_weinstein · 2026-11-19
- Anthropic's IPO is tomorrow, and San Francisco is already celebrating the liquidity event — nmasc_ · 2026-11-19
- Vercel crosses $700M annualized revenue, up 180% YoY, as agents drive deployments — cramforce · 2026-11-19
- Google manual actions surge: risky GEO/AEO tactics triggering scaled content abuse penalties — gaganghotra_ · 2026-11-19